Literature DB >> 3168395

Increased nonrenal clearance and increased diuretic efficiency of furosemide in cystic fibrosis.

G Alván1, B Beermann, L Hjelte, M Lind, A Lindholm, B Strandvik.   

Abstract

The pharmacokinetics of furosemide and its diuretic effect were studied in six patients with cystic fibrosis (CF) and in six age-matched healthy volunteers. Furosemide was given intravenously at a dose of approximately 0.5 mg/kg. Renal excretion of furosemide was decreased in CF because nonrenal clearance was more than twice as high as in controls (p = 0.03). Nonrenal clearance correlated with the volume of distribution (r2 = 0.52, p = 0.01), which makes a difference in the distribution and binding determinants for clearance. Another reason for increased nonrenal clearance could be induction of drug metabolism in CF, but the excretion of furosemide conjugate did not differ significantly between the groups. Although 26% less furosemide was excreted in CF than in controls (p = 0.03), the diuretic response (calculated as excretion of water and electrolytes) did not differ. Thus the diuretic efficiency was higher in CF for Na+ (p = 0.02), Cl- (p = 0.01), K+ (p = 0.07), and volume (p = 0.005). This difference is probably secondary to the different rates of delivery of furosemide into urine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3168395     DOI: 10.1038/clpt.1988.177

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

1.  Sedation with Propofol for Bronchoscopy in Cystic Fibrosis Lung Transplant Recipients.

Authors:  Carrie Ho; Don Hayes; Medhi Khosravi; Mark L Splaingard; Dmitry Tumin; Eric A Lloyd
Journal:  Lung       Date:  2018-05-24       Impact factor: 2.584

Review 2.  Drug disposition in cystic fibrosis.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

Review 3.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

4.  Diuretic effect and disposition of furosemide in cystic fibrosis.

Authors:  J Prandota; I J Smith; B C Hilman; J T Wilson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  The efficiency concept in pharmacodynamics.

Authors:  G Alván; G Paintaud; M Wakelkamp
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

6.  Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis.

Authors:  R Demnati; M C Michoud; A Jeanneret-Grosjean; H Ong; P Du Souich
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

7.  Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients.

Authors:  B A Christensson; I Nilsson-Ehle; B Ljungberg; A Lindblad; A S Malmborg; L Hjelte; B Strandvik
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

8.  Diuretic effect and diuretic efficiency after intravenous dosage of frusemide.

Authors:  G Alván; L Helleday; A Lindholm; E Sanz; T Villén
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

9.  Pharmacokinetics and effects of frusemide in patients with the nephrotic syndrome.

Authors:  P A Sjöström; B G Odlind; B A Beermann; B E Karlberg
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 10.  Altered intravenous drug disposition in people living with cystic fibrosis: A meta-analysis integrating top-down and bottom-up data.

Authors:  Pieter-Jan De Sutter; Maxime Van Haeverbeke; Eva Van Braeckel; Stephanie Van Biervliet; Jan Van Bocxlaer; An Vermeulen; Elke Gasthuys
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-06-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.